Key Words:
peptides, cancer cells, mutant p53
The purpose of this invention is for detecting and killing cancer cells that express
oncogenic mutant p53 (mtp53) proteins. Over 70% of all cancers over express mutant p53
proteins. This invention will for the first time , utilize the critical biomarker mtp53 as both a
therapeutic and diagnostic vehicle (ie it is a mtp53 theranostic). The present invention relates to
using p53 oligomerization domain peptides as a means to de tect cancers with stable mtp53 and
also to directly target such cancers for DNA damage mediated cell death. The present invention
relates to methods of noninvasive imaging and treating disorders associated with high levels of
mtp53 protein expression.
For more information or to license this innovation:
- Log In
to view the innovation's details
- Sign Up
with discount code "ECOS"
